

Special Issue

Drug Treatment of Thyroid Cancer

Message from the Guest Editors

Thyroid cancer (TC), the most common endocrine malignancy, has become a relevant public health problem. Tumors derived from follicular cells constitute a majority of the thyroid neoplasms. Conventional treatment includes surgery, radioactive iodine therapy, and the suppression of thyroid hormones and has shown its effectiveness in most cases. However, there is currently a notable therapeutic challenge for more aggressive cases with recurrent or advanced local metastatic disease or I131-refractory thyroid cancers. Research related to treatment has progressed, including immunotherapies and precision medicine, and new molecules have come into practice, targeting specific genetic changes with a positive effect on survival rates in aggressive and refractory cases.

Guest Editors

Dr. Cristina Alina Silaghi

Prof. Dr. Carmen Emanuela Georgescu

Dr. Horațiu Silaghi

Dr. Cristina Pop

Deadline for manuscript submissions

25 August 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/220269

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)